Jump to start of content

Complete requirements by 12/31/18 to avoid a change in certification status Expand/Collapse the ABIM alert.

Sign in to your Physician Portal to view any remaining requirements for the year. Not completing these requirements by 12/31/18 could result in a change to your certification status.

Breadcrumb trail:

Gastroenterology Board

Expand All | Collapse All

Jane E. Onken, MD, Chair

Jane E. Onken, MDDr. Onken is an Associate Professor of Medicine, Division of Gastroenterology at Duke University Medical Center. She is Director of the Inflammatory Bowel Disease clinic at Duke and on faculty at the Duke Clinical Research Institute. She is board certified in Gastroenterology.

Dr. Onken is Chair of the American Board of Internal Medicine (ABIM) Gastroenterology Board and a member of the ABIM Council. She recently completed a three-year term as Chair of the Education and Training Committee of the American Gastroenterological Association (AGA). During that term, she served on the AGA's Leadership Cabinet, the Maintenance of Certification Task Force, and the Board of the Academy of Educators. She has chaired the AGA Training Subcommittee and been a member of the Graduate Training Examination Subcommittee. In 2013, she was selected to join the multi-society Oversight Working Network Committee, a group that designed the Entrustable Professional Activities currently in use by training programs in Gastroenterology. At Duke, she was recently elected for a fourth term to the University's Academic Council and has served on the Executive Committee of the Academic Council. Dr. Onken is a former program director for the Duke Gastroenterology Fellowship program. She is a member of the Leadership Board of the Triangle Chapter of the Crohn's and Colitis Foundation of America (CCFA) and is a recipient of the CCFA Premier Physician Award.

Dr. Onken received her undergraduate degree from Smith College and attended the George Washington University School of Medicine. She completed her house staff training in internal medicine at Duke University, followed by fellowship training in gastroenterology. She received a master's degree in health sciences from Duke in 2005.

As of January 2017, Dr. Onken reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to Duke University, from the following company:

  • Seres Therapeutics, for a study investigating fecal replacement for patients with mild-to-moderate ulcerative colitis.

Dr. Onken serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Gastroenterological Association, Chair of Education and Training Committee, Member of Leadership Cabinet, Board Member of Academy of Educators, receiving reimbursement for travel expenses.

Kenneth R. DeVault, MD

Dr. DeVault is Professor and Chair of the Department of Medicine at Mayo Clinic Florida. He is a member of the Executive Operating Team of Mayo Clinic in Florida and is the Medical Director for Leadership and Organizational Development. Dr. DeVault is board certified in Internal Medicine and Gastroenterology.

Prior to becoming Chair of Medicine, Dr. DeVault was Chair of the Division of Gastroenterology and Hepatology at the Mayo Clinic Florida from 2005-2010. He is a member of the American Board of Internal Medicine Gastroenterology Board. Dr. DeVault is a Fellow of and immediate past president of the American College of Gastroenterology. He is also a member of the American Gastroenterological Association, American Society for Gastrointestinal Endoscopy and a fellow of the American College of Physicians.

Dr. DeVault conducts research on disorders affecting all aspects of the esophagus and has written more than 250 book chapters, abstracts, editorials and original articles on subjects ranging from treatment of GERD, dysphagia, esophagitis and Barrett's esophagus to laparoscopic anti-reflux surgery and managed care issues in the treatment of GERD. He also has interest in gastrointestinal health in the third world, improving professionalism in both trainees and practicing physicians and in the development of a diverse and effective health care work force.

He received his undergraduate degree from the University of Tennessee and his medical degree from the Bowman Gray School of Medicine at Wake Forest University. He completed his internship and residency in internal medicine at Vanderbilt University and completed a combined clinical and research fellowship at Jefferson Medical College.

As of July 2017, Dr. Devault reported the following external relationships:

Funding for clinical trial expenses, paid to the Mayo Clinic, from the following company:

  • Takeda, for an investigator-initiated clinical trial on irritable bowel syndrome and intestinal inflammation.

Dr. DeVault serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Gastroenterology, Officer and Trustee, receiving honoraria reimbursement for travel expenses.

Lawrence S. Friedman, MD

Dr. Friedman, a board certified internist and gastroenterologist, is the Anton R. Fried, MD, Chair, Department of Medicine, Newton-Wellesley Hospital; Assistant Chief of Medicine, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School; and Professor of Medicine, Tufts University School of Medicine.

He is co-editor of Sleisenger and Fordtran's “Gastrointestinal and Liver Disease,” “Handbook of Liver Disease” and “Essentials of Gastroenterology.” He is a consultant to the FDA Antimicrobial Drugs Advisory Committee, a current member and former Chair of the American Board of Internal Medicine's Gastroenterology Board, past Chair of the Multisociety Task Force on GI Training and past Chair of the Digestive Disease Week Council.

He has received the Christian R. and Mary F. Lindback Award for Distinguished Teaching (at Jefferson Medical College), the Alfred Kranes Award for Excellence in Clinical Teaching (at Massachusetts General Hospital), the Distinguished Service Award from the American Society for Gastrointestinal Endoscopy, and the Distinguished Educator Award from the American Gastroenterological Association.

Dr. Friedman attended Princeton University and received his undergraduate and medical degrees from the Johns Hopkins University School of Medicine combined BA/MD program. He did his residency training at The Johns Hopkins Hospital, followed by a clinical and research fellowship in gastroenterology at Harvard Medical School and Massachusetts General Hospital in Boston.

As of January 2017, Dr. Friedman reported the following external relationships:

Work as an author or editor for following companies, with compensation as listed:

  • American Society for Gastrointestinal Endoscopy, receiving compensation as an editor.
  • Elsevier, receiving compensation as an editor.
  • McGraw-Hill, receiving compensation as an author.
  • UpToDate, receiving compensation as both editor and author.
  • Wiley, receiving compensation as an editor.

Dr. Friedman serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Newton-Wellesley Hospital, Board of Trustees, without compensation.

Dr. Friedman is also a member of the Antimicrobial Drugs Advisory Committee with the Food and Drug Administration, and a member of the Board of Trustees at Newton-Wellesley Hospital.

Sunanda V. Kane, MD

Dr. Kane is currently Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota. She is board certified in both Internal Medicine and Gastroenterology. Dr. Kane has a busy clinical practice, and she teaches and conducts research in the area of inflammatory bowel disease. Her main interests are in medication compliance and its effects on disease outcomes, as well as gender-specific issues.

Dr. Kane serves on the American Board of Internal Medicine (ABIM) Gastroenterology Board and formerly served on the ABIM Gastroenterology Self-Assessment Committee. She is the Director of the recently created Quality Council of the American College of Gastroenterology (ACG) and serves on the ACG Institute Board. She is also the Chair of Quality for the Division of Gastroenterology and Hepatology at Mayo Clinic. She was previously on the Board of Trustees for the ACG and served as Chair for the ACG Women's Committee as well as the Chair of the National Patient Education Committee for the Crohn's & Colitis Foundation of America.

Dr. Kane holds a medical degree from Rush Medical College in Chicago. She did her internship and residency at Rush-Presbyterian-St Luke's Medical Center in Chicago and a fellowship at the University of Chicago. She also holds a master's degree in epidemiology and biostatistics.

As of January 2017, Dr. Kane reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the Mayo Clinic, from the following companies:

  • AbbVie, for an open-label trial of adalimumab for Crohn's disease.
  • Amgen, for a trial of a new interleukin for ulcerative colitis.
  • Janssen Pharmaceutica, for an open-label trial of ustekinumab for Crohn's disease.
  • Janssen Pharmaceutica, for an open-label trial of golimumab trial for ulcerative colitis.
  • Pfizer, for a trial of tofacitinib for ulcerative colitis.
  • Takeda Pharmaceutical Company, for an open-label trial of vedolizumab for Crohn's disease.

Service on data and safety monitoring board for the following company:

  • Shire, for study for the treatment of newly diagnosed pediatric ulcerative colitis, without compensation.

Service on a research-related expert panel or advisory board for the following company, with honoraria paid to Mayo Clinic:

  • UCB Pharma, serving on an advisory board to develop a model for predicting disease response based on data from registration trials.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with compensation as listed:

  • UCB, consulting on development of a clinical trial for pregnant women with Crohn's disease, receiving honoraria, paid to the Mayo Clinic.

Post-marketing clinical research, with funding for research staff provided to the Mayo Clinic, from the following company:

  • UCB, to study the Mayo experience with certolizumab pegol for Crohn's disease.

Dr. Kane also reported receives pharmacy services from Currant Health in support of a study on adalimumab.

Work as an author or editor for following companies, with compensation as listed:

  • American Gastroenterology Association Press, receiving royalties for book sales.
  • Mayo Clinic Scientific Press, receiving royalties for contribution to textbook Mayo Clinic Gastroenterology and Hepatology Board Review.

Dr. Kane serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • 11 Health, Advisory Board, receiving reimbursement for travel expenses.
  • American College of Gastroenterology, Board of Trustee, Treasurer, receiving reimbursement for travel expenses.

Funding for clinical trial expenses and salary support, paid to the Mayo Clinic, from the following organizations:

  • Crohn's & Colitis Foundation of America, for participation as one site in a multi-center grant to study pregnant women with Crohn's Disease.
  • Crohn's & Colitis Foundation of America, to support a study on the effects of medications on post-operative outcomes.

Dr. Kane serves as a member of the Board of Advisors for the Gastrointestinal Health Foundation, a non-profit organization that provides CME educational programs on topics related to gastrointestinal health, supported by educational grants from pharmaceutical companies.

Dr. Kane serves as a member for the Selection Committee for the Sherman Prize for Excellence in Fighting Crohn's and Colitis, run by Arabella Advisors, with compensation for travel and time.

Nancy S. Reau, MD

Dr. Reau, who is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology, is currently Associate Director of Solid Organ Transplantation and Section Chief of Hepatology at Rush University Medical Center.

She previously served as Assistant Professor of Medicine at Rush University in Chicago from 2002 to 2005. She became an Associate Professor of Medicine in 2010, Medical Director of Hepatology Clinical and Translational Research in 2015 and then joined Rush University Medical Center in 2015.

Dr. Reau's research interest is in viral hepatitis, both in drug development as well as utilization. She is currently a member of the American Board of Internal Medicine Gastroenterology Board, the American Association for the Study of Liver Diseases (AASLD) steering committee for the hepatitis C special interest group, and the AASLD/IDSA Practice Guidelines for hepatitis C. She served as Chair of the AASLD public policy committee. Additionally, Dr. Reau is a member of the American College of Gastroenterology women's training committee. She has been a member of the national board of directors of the American Liver Foundation (ALF) and served as the president of the Illinois chapter. She is currently co-Chair of the National ALF Medical Advisory Committee and serves on multiple advisory boards including Medscape and Medivo.

Dr. Reau received her bachelor's degree at Oberlin College in Oberlin, Ohio. She received her medical degree, cum laude, and completed a medicine residency and gastroenterology fellowship at The Ohio State University in Columbus, Ohio. She went to The Johns Hopkins Medical Center in Baltimore, MD, where she did her advanced transplant hepatology fellowship in 2001.

As of January 2017, Dr. Reau reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Chicago, from the following company:

  • AbbVie, to support NextGen studies.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Abbott, advising on technology for hepatitis B and hepatitis C, receiving honoraria.
  • AbbVie, serving on a national advisory board for clinical development in hepatitis C, receiving travel reimbursement and honoraria.
  • Gilead, serving on a national advisory board for clinical development in hepatitis C, receiving travel reimbursement and honoraria.
  • Merck, advising on national and global development in hepatitis C, receiving travel reimbursement and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with compensation as listed:

  • Medscape, consulting on viral hepatitis education, receiving honoraria.

Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:

Dr. Reau develops educational content for continuing medical education on hepatitis C and provides an update to the American Association for the Study of Liver Disease for Clinical Care Options, receiving honoraria. Clinical Care Options is a medical education company that develops educational content and decision support tools.

Dr. Reau develops educational content for continuing medical education on hepatitis C receiving honoraria from the Chronic Liver Disease Foundation, which receives support from educational grants from multiple pharmaceutical companies

Dr. Reau develops and delivers educational content for continuing medical education on hepatitis C for PRIME, receiving reimbursement for travel expenses and honoraria. PRIME is a medical education company which receives support from educational grants from multiple pharmaceutical companies.

Dr. Reau develops and delivers educational content for continuing medical education on hepatitis C for Vindico, receiving reimbursement for travel expenses and honoraria. Vindico is a medical education company which receives support from educational grants from multiple pharmaceutical companies.

Dr. Reau serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Association for the Study of Liver Disease, Member of the Steering Committee for the Hepatitis C Special Interest Group, without compensation.
  • American College of Gastroenterology, Member of the Training Committee, without compensation.
  • Primrose Healthcare, Advisory Board Member, receiving consulting fees.

Colleen M. Schmitt, MD

Dr. Schmitt is a board certified internist and gastroenterologist. She has practiced as a consultant in gastroenterology in Chattanooga, Tennessee, with the multispecialty Galen Medical Group since 1993.

Currently, Dr. Schmitt is a member of the American Board of Internal Medicine Gastroenterology Board. She is a past President of the American Society for Gastrointestinal Endoscopy (ASGE) and has served on and chaired the Health and Public Policy Committee of the ASGE. She has co-chaired the Research Committee for the American College of Gastroenterology, and the ad hoc Committee on Outcomes Research for the ASGE. She served as Chief of the Gastroenterology division, the University of Tennessee College of Medicine, Chattanooga, where she was also Director of Clinical Research.

Dr. Schmitt has worked in health and policy at the local, state and national levels, and helped develop the Volunteers in Medicine Clinic, Chattanooga, where she has served on the Board, as well as on the Board of the Chattanooga & Hamilton County Medical Society.

Dr. Schmitt obtained her medical degree at the University of South Alabama, Mobile, and then completed her internship and residency in internal medicine at Beth Israel Hospital in Boston. She completed a fellowship in gastroenterology at Duke University Medical Center and a joint fellowship in health services research at the Durham VA Hospital, where she earned a master's degree in biometry and informatics.

As of May 2017, Dr. Schmitt reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Galen Medical Group, from the following company:

  • Merck, for a study of a vaccine for Clostridium difficile infection.

Industry-supported continuing medical education supported by the following companies, paid to the American Society for Gastrointestinal Endoscopy, with compensation as listed:

  • Boston Scientific, for the Leadership, Education and Development Program by the American Society for Gastrointestinal Endoscopy, receiving reimbursement for travel expenses and funding for project expenses.
  • Pentax, for the Leadership, Education and Development Program by the American Society for Gastrointestinal Endoscopy, receiving reimbursement for travel expenses and funding for project expenses.

Dr. Schmitt serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • Tennessee Gastro, Board of Directors for Clinically Integrated Network, without compensation.

Dr. Schmitt is also a medical director for AMSURG Digestive Disorders Endoscopy Center.

Laura D. Wingate, BA

Ms. Wingate is Senior Vice President, Education, Support, & Advocacy for the Crohn's & Colitis Foundation, where she oversees patient and professional education, state and federal advocacy, and support programming for the Foundation. She works in conjunction with the Crohn's & Colitis Foundation National Scientific Advisory Committees and numerous patient volunteers on developing all programs and resources.

Prior to this, Ms. Wingate was Director of Operations for Clown Care & Vaudeville Caravan Programs, where she worked for eight years in providing professional entertainers to pediatric and geriatric centers across the United States. She began her career as an Administrative Coordinator at Memorial Sloan Kettering Cancer Center, where she advised and implemented quality improvement initiatives including the redesign of the outpatient center focused on streamlining the patient’s experience.

She currently serves as a member of the American Board of Internal Medicine Gastroenterology Board.

Ms. Wingate holds a bachelor's degree in arts, health and society from the University of Rochester, and has completed master’s degree coursework at New York University’s Robert F. Wagner Graduate School for Public Service.

As of May 2018, Ms. Wingate reported no external relationships.